Core Viewpoint - Autonomix Medical, Inc. has strengthened its intellectual property position in the nerve-mapping and denervation space with the issuance of U.S. Patent No. 12,257,071, which supports its mission to advance minimally invasive, nerve-focused therapeutics [1][2]. Patent and Technology - The newly issued '071 patent relates to advanced catheter-based systems that combine nerve mapping and radiofrequency (RF) ablation technologies, enhancing precision in treating nerve-related conditions [1][3]. - Key features of the '071 patent include deployable microfingers with embedded sensors for real-time physiological monitoring, the ability to map, stimulate, ablate, and assess nerve activity in a single integrated system, and feedback-driven control of multiple types of procedures [3][4]. - The technology is designed to treat conditions influenced by sympathetic nerve activity, including renal denervation for hypertension, chronic pain syndromes, and various metabolic and neurological disorders [3][4]. Clinical Development and Future Plans - The company plans to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 to support commercialization of the Autonomix Sensing and RF Ablation System as a treatment for pancreatic cancer pain [5][7]. - Autonomix's technology platform aims to revolutionize the diagnosis and treatment of diseases involving the nervous system, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain [6][7]. Market Position and Strategy - The issuance of the patent marks a key milestone in the company's strategy to transform pain management and treat neurological disorders through minimally invasive, catheter-based denervation [2][4]. - The company currently holds over 80 issued patents and 40 pending patent applications, indicating a strong and expanding global patent portfolio [1][2].

Core Viewpoint - Autonomix Medical, Inc. is participating in the Virtual Investor Closing Bell Series to showcase its innovative medical device technology focused on precision nerve-targeted treatments [2][3]. Company Overview - Autonomix Medical, Inc. is a medical device company dedicated to advancing technologies for diagnosing and treating diseases related to the nervous system [5]. - The company's first-in-class platform system technology features a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [5][6]. Technology and Applications - The initial development of the technology is aimed at treating pain, specifically targeting pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [6]. - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management, across various diseases [6]. Event Details - The event will feature a corporate overview by Brad Hauser, President and CEO, and will include a live Q&A session for investors and interested parties [3][4]. - The live video webcast will be accessible on the company's website, with a replay available for 90 days following the event [4].

Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Access Here Additional indications potentially double the addressable market beyond pancreatic cancer pain Follow-on expansion phase expected to begin in Q2 2025 THE WOODLANDS, TX, May 13, 2025 (GLOBE NEWSWIRE) -- – Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to rev ...

Core Insights - Autonomix Medical, Inc. has successfully completed the initial phase of its first-in-human proof-of-concept trial ("PoC 1") demonstrating clinically meaningful pain reduction in patients with pancreatic cancer pain [1][2] - The company plans to initiate a market expansion study ("PoC 2") targeting additional visceral cancers and earlier stage pancreatic cancer, expected to commence in Q2 2025 [1][2] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases involving the nervous system [3] - The company's platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [3] - The initial development of this technology is aimed at treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options [4] Future Prospects - The technology has the potential to address a wide range of indications beyond pancreatic cancer, including cardiology, hypertension, and chronic pain management [4] - The investigational technology has not yet received marketing clearance in the United States [4]

Core Insights - Autonomix Medical, Inc. has successfully completed the initial trial phase ("PoC 1") for its innovative pain management technology, demonstrating significant pain reduction in patients with severe pancreatic cancer pain [1][2][5] - The company plans to initiate a follow-on market expansion study ("PoC 2") in Q2 2025, targeting additional visceral cancers and earlier stage pancreatic cancer, potentially doubling the addressable market [1][6][12] Group 1: Trial Results - The PoC 1 trial enrolled 20 patients, achieving clinically meaningful pain reduction with 100% of responders reporting zero opioid use at 7 days post-procedure and 73% remaining opioid-free at 4-6 week follow-up [1][2][8] - Pain relief was statistically significant, with a mean reduction of 3.32 on the Visual Analog Scale (VAS) at 7 days (baseline 7.61 to 4.29), representing a 43.6% improvement, and a mean reduction of 3.95 at 4-6 weeks (baseline 7.95 to 4.00), or 49.7% improvement [8][11] - Responding patients treated via femoral access showed a mean pain reduction of 4.16 at 7 days (baseline 7.81 to 3.65), or 53.3% improvement, and 4.67 at 4-6 weeks (baseline 7.89 to 3.22), or 59.2% improvement [8][11] Group 2: Safety and Quality of Life - The procedure demonstrated a strong safety profile, with no device or procedure-related serious adverse events reported, although there were 8 serious adverse events unrelated to the procedure [8][11] - Patients reported a 76% improvement in global quality of health at 7 days and a 42% improvement at 4-6 weeks post-procedure [8][11] Group 3: Future Directions - The follow-on PoC 2 phase will focus on interventional pain management for additional visceral cancers and earlier stage pancreatic cancer, with an amended trial protocol to gather more data on pain management [6][7][9] - Autonomix's technology platform has the potential to address a wide range of indications beyond cancer pain, including cardiology and chronic pain management [7][12][13]

New patent underscores breadth of application and expansion opportunities for Company's catheter-based technology Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, April 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, t ...

Core Viewpoint - Autonomix Medical, Inc. is preparing to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval of its innovative medical technology aimed at diagnosing and treating diseases of the nervous system [1][3]. Company Overview - Autonomix Medical, Inc. is focused on advancing technologies for the diagnosis and treatment of nervous system diseases, featuring a first-in-class platform system technology that includes a catheter-based microchip sensing array [4]. - The technology is designed to detect and differentiate neural signals with up to 3,000 times greater sensitivity than existing technologies, enabling transvascular diagnosis and treatment of peripheral nervous system diseases [4]. Clinical Development - The company is initially developing its technology for pain treatment, specifically targeting pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [5]. - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management [5]. Expert Engagement - Autonomix has engaged a team of U.S. and international medical experts in interventional radiology and cancer pain to guide its clinical and regulatory path, ensuring that pre-clinical and clinical studies align with the needs for the FDA De Novo submission expected in 2026 [1][2][3].

Core Insights - Autonomix Medical, Inc. announced that an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO) [1] Company Overview - Autonomix is a medical device company focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system [4] - The company's first-in-class platform technology includes a catheter-based microchip sensing array that can detect and differentiate neural signals with up to 3,000 times greater sensitivity than current technologies [4] - The initial development of this technology targets pain management, specifically for pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [5] - The technology has potential applications across various indications, including cardiology, hypertension, and chronic pain management [5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5] Event Details - The poster presentation at ECIO 2025 is titled "Catheter-Based Transvascular RF Neural Ablation for Severe Pancreatic Cancer Pain: First Results from The Elpis Study" [2] - The conference is recognized as a comprehensive platform for interventional oncology education, featuring over 140 lectures and 16 hands-on training sessions [2]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [3] - The company is developing a first-in-class platform system technology that includes a catheter-based microchip sensing array, which may detect and differentiate neural signals with approximately 3,000 times greater sensitivity than current technologies [3] - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which is known for causing debilitating pain and lacks reliable treatment options [4] Stock Option Grant - The Compensation Committee of Autonomix's Board of Directors approved an inducement stock option grant on March 17, 2025, for a new non-executive employee to purchase 7,500 shares of common stock [1] - The exercise price of the options is equal to the closing price of Autonomix's common stock on the grant date, and the options have a ten-year term, vesting in four equal annual installments [2]

Core Insights - Autonomix Medical, Inc. has made significant advancements in its patent portfolio, now holding over 80 issued patents and 40 pending applications, which strengthens its proprietary technology in the medical device sector [1][5] - The company’s proprietary sensing and ablation technology shows promise in precisely targeting and eliminating overactive nerves, which could enhance patient outcomes across various medical conditions [1][3] Patent and Technology Developments - The United States Patent and Trademark Office has issued U.S. patent 12,217,863, which protects Autonomix's technology for capturing and processing physiological signals, applicable in heart mapping, arterial mapping, and central nervous system monitoring [1][4] - The technology platform utilizes a catheter-based microchip sensing array that can detect neural signals with up to 3,000 times greater sensitivity than existing technologies, enabling a more effective approach to treating chronic pain and other conditions [3][5] Clinical Applications and Future Plans - Autonomix is initially focusing on the treatment of pancreatic cancer pain, with plans to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 [4][6] - The technology has potential applications beyond cancer pain, including conditions related to hypertension and chronic pain management, indicating a broad spectrum of future indications [2][6]